Neuroendokrine Neoplasien im Gastrointestinaltrakt: neue individualisierte Therapieansätze

Schlüsselwörter

neuroendokrine Neoplasie - WHO-Klassifikation - molekular zielgerichtete Therapie

Keywords

neuroendocrine neoplasia - WHO classification - targeted molecular therapy

Literatur

• 1 Ahmed A, Turner G, King B. et al . Midgut neuroendocrine tumours with liver metastases:.  Endocr Relat Cancer. 2009;  16 885-894
• 2 Arnold R, Trautmann M E, Creutzfeldt W. et al . Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.  Gut. 1996;  38 430-438
• 3 Bahra M, Jacob D, Pascher A. et al . Surgical strategies and predictors of outcome for malignant neuroendocrine tumors of the pancreas.  J Gastroenterol Hepatol. 2007;  22 930-935
• 4 Ben-Shlomo A, Melmed S. Drug profile: Pasireotide – a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing’s disease.  IDrugs. 2007;  10 885-895
• 5 Berber E, Flesher N, Siperstein A E. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases.  World J Surg. 2002;  26 985-990
• 6 Bushnell D L, O’Dorisio T M, O’Dorisio M S. et al . 90Y-Edotreotide for metastatic carcinoid refractory to octreotide.  J Clin Oncol. 2010;  28 1652-1659
• 7 Doerffel Y, Wermke W. Neuroendocrine tumors: characterization with contrast-enhanced ultrasonography.  Ultraschall Med. 2008;  29 506-514
• 8 Ekeblad S, Sundin A, Janson E T. et al . Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.  Clin Cancer Res. 2007;  13 2986-2991
• 9 Eriksson J, Stalberg P, Nilsson A. et al . Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors.  World J Surg. 2008;  32 930-938
• 10 Ezziddin S, Logvinski T, Yong-Hing C. et al . Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.  J Nucl Med. 2006;  47 223-233
• 11 Ezziddin S, Opitz M, Attassi M. et al . Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy.  Eur J Nucl Med Mol Imaging. 2011;  38 459-466
• 12 Faiss S, Pape U F, Böhmig M. et al . Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon-alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors.  J Clin Oncol. 2003;  21 2689-2696
• 13 Faivre S, Debaldo C, Vera K. et al . Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.  J Clin Oncol. 2006;  24 25-35
• 14 Givi B, Pommier S EJ, Thompson A K. et al . Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival.  Surgery. 2006;  140 891-898
• 15 Hanahan D, Weinberg R A. Hallmarks of cancer: the next generation.  Cell. 2011;  144 646-674
• 16 Hellman P, Ladjevardi S, Skogseid B. et al . Radiofrequency tissue ablation using cooled tip for liver metastases of neuroendocrine tumors.  orld J Surg. 2002;  26 1052-1056
• 17 Jann H, Roll S, Couvelard A. et al . Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome.  Cancer. 2011;  117 3332-3341
• 18 King J, Quinn R, Glenn D M. et al . Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.  Cancer. 2008;  113 921-929
• 19 Klimstra D S. et al .In: Bosman FT, Carneiro F, Hruban RH, Theise ND WHO Classification of Tumours of the Digestive System. Lyon; IARC 2010
• 20 Kulke M H, Hornick J L, Frauenhoffer C. et al . O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.  Clin Cancer Res. 2009;  15 338-345
• 21 Kulke M H, Lenz H J, Meropol N J. et al . Activity of Sunitinib in patients with advanced neuroendocrine tumors.  J Clin Oncol. 2008;  26 3403-3410
• 22 Kwekkeboom D J, deHerder W W, Kam B L. et al . Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival.  J Clin Oncol. 2008;  26 2124-2130
• 23 Marrache F, Vuillerme M P, Roy C. et al . Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours.  Br J Cancer. 2007;  96 49-55
• 24 Moertel C G, Kvols L K, O’Connel M J. et al . Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin.  Cancer. 1991;  68 227-232
• 25 Moertel C G, Lefkopoulo M, Lipsitz S. et al . Streptozotocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma.  N Engl J Med. 1992;  326 519-523
• 26 Niederle M B, Hackl M, Kaserer K. et al . Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification.  Endocr Relat Cancer. 2010;  17 909-918
• 27 Otte A, Mueller-Brand J, Dellas S. et al . Yttrium-90-labelled somatostatin-analogue for cancer treatment.  Lancet. 1998;  351 417-418
• 28 Pape U F, Berndt U, Müller-Nordhorn J. et al . Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.  Endocr Relat Cancer. 2008;  15 1083-1097
• 29 Pape U F, Böhmig M, Berndt U. et al . Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center.  Ann NY Acad Sci. 2004;  1014 222-233
• 30 Pape U F, Jann H, Müller-Nordhorn J. et al . Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.  Cancer. 2008;  113 256-265
• 31 Pascher A, Steinmüller T, Radke C. et al . Primary and secondary hepatic manifestation of neuroendocrine tumors.  Langenbeck’s Arch Surg. 2000;  385 265-270
• 32 Pavel M E, Baum U, Hahn E G. et al . Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors.  Int J Gastrointest Cancer. 2005;  35 179-186
• 33 Pavel M E, Baum U, Hahn E G. et al . Efficacy and tolerability of Pegylated IFN-α in patients with neuroendocrine gastroenteropancreatic carcinomas.  J Interferone Cytokine Res. 2006;  26 8-13
• 34 Pietras K, Hanahan D. A Multitargeted, metronomic, and maximum-tolerated dose ‘‘chemo-switch’’ regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.  J Clin Oncol. 2005;  23 939-952
• 35 Plöckinger U, de Herder W W, Wiedenmann B (Hrsg). Consensus guidelines for the standard of care for patients with digestive neuroendocrine tumors.  Neuroendocrinology. 2009;  90 159-234
• 36 Plöckinger U, Kloeppel G, Wiedenmann B. et al . The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors.  Neuroendocrinology. 2009;  90 349-363
• 37 Raymond E, Dahan L, Raoul J L. et al . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.  N Engl J Med. 2011;  364 501-513
• 38 Rindi G, Klöppel G, Ahlmann H. et al . TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system.  Virchows Arch. 2006;  449 395-401
• 39 Rindi G, Klöppel G, Couvelard A. et al . TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system.  Virchows Arch. 2007;  451 757-762
• 40 Rinke A, Müller H H, Schade-Brittinger C. et al . Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.  J Clin Oncol. 2009;  27 4656-4663
• 41 Ruf J, Schiefer J, Furth C. et al . 68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol.  J Nucl Med. 2011;  52 697-704
• 42 Ruutiainen A T, Soulen M C, Tuite C M. et al . Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver.  J Vasc Interv Radiol. 2007;  18 847-855
• 43 Sobin L H, Gospodarowicz M K, Wittekind C. TNM classification of malignant tumours. Wiley & Blackwell. Oxford; 2009
• 44 Strosberg J R, Fine R L, Choi J. et al . First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.  Cancer. 2011;  117 268-275
• 45 Wolin E M, Kvols L, Ezzat S. et al . Pasireotide LAR in patients with metastatic carcinoid tumors: pharmacokinetics (PK) and safety results from a randomized, multicenter, phase I study.  Abstract Proc ASCO. 2009; 
• 46 Yao J C, Hassan M, Phan A. et al . One hundred years after „carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.  J Clin Oncol. 2008;  26 3063-3072
• 47 Yao J C, Lombard-Bohas C, Baudin E. et al . Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy.  J Clin Oncol. 2010;  28 69-71
• 48 Yao J C, Phan A, Hoff P M. et al . Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b.  J Clin Oncol. 2008;  26 1316-1323
• 49 Yao J C, Shah M H, Ito T. et al . Everolimus for advanced pancreatic neuroendocrine tumors.  N Engl J Med. 2011;  364 514-523
• 50 Zitzmann K, De Toni E M, Brand S. et al . The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.  Neuroendocrinology. 2007;  85 54-60

1 Widmung Herrn Chefarzt i.R. Dr. med. Joachim Quäck posthum in Hochachtung, Verehrung und Zuneigung gewidmet.